Adjuvant therapy for stage II melanoma: the need for further studies
-
Published:2023-08
Issue:
Volume:189
Page:112914
-
ISSN:0959-8049
-
Container-title:European Journal of Cancer
-
language:en
-
Short-container-title:European Journal of Cancer
Author:
Lee RebeccaORCID,
Mandala MarioORCID,
Long Georgina V.,
Eggermont Alexander M.M.,
van Akkooi Alexander C.J.,
Sandhu Shahneen,
Garbe Claus,
Lorigan PaulORCID
Funder
Wellcome Trust
NHMRC
University of Sydney
Subject
Cancer Research,Oncology
Reference58 articles.
1. Adjuvant Pembrolizumab versus placebo in resected stage III melanoma;Eggermont;N Engl J Med,2018
2. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial;Eggermont;Lancet Oncol,2021
3. Five-year analysis of adjuvant Pembrolizumab or placebo in stage III melanoma;Eggermont;NEJM Evid,2022
4. Adjuvant Nivolumab versus Ipilimumab in resected stage III or IV melanoma;Weber;N Engl J Med,2017
5. Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial;Ascierto;Lancet Oncol,2020
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献